UNSPSC 51262503: Guanoxan

This classification denotes a guanidine and antihypertensive agent with the molecular formula C10H13N3O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 9V0MRL0R5Y, chemically known as guanidine, ((2,3-dihydro-1,4-benzodioxin-2-yl)methyl)- (9ci) but generally known as guanoxan, which bears US NIH Compound Identifier 16564. European Medicines Agency schedules Guanoxan in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07989MIG.

UNSPSC 51262503 Guanoxan is a Commodity code that captures pharmaceutical products and drug-related systems procured by state and local health agencies. Recent opportunities under this code show state and local governments buying naloxone (opioid antagonist) and drug deactivation systems for public health and emergency response programs, as well as exploring direct-to-manufacturer pharmacy prescription fulfillment models. The scope spans both tangible pharmaceutical supplies and pharmacy benefit program infrastructure. Issuing bodies include county health departments (Seminole County, Florida) and state health and human services commissions (Texas HHS Commission), signaling activity across local health agencies and state-level pharmacy administration.

Geographically, the code shows recent activity in Florida and Texas. Seminole County's IFB for 1,900 units of naloxone and 800 safe drug deactivation systems annually, posted June 30, 2026, with a response deadline of July 26, 2023, represents direct procurement of pharmaceutical supplies for community health initiatives with quarterly deliveries to a county health facility. The Texas HHS Commission's RFI HHS0017013, posted April 3, 2026, represents exploratory procurement for direct-to-manufacturer prescription programs designed to restructure pharmacy benefit delivery outside traditional pharmacy benefit manager and wholesaler channels. The RFI seeks vendor capabilities for negotiated net pricing models and outcomes-based agreements serving self-insured employers and government health plans. Neither opportunity specifies set-aside designations or budget ranges at the posted stage.